Roivant Sciences Announces FDA Approval of LISRAYA for Dermatomyositis

What Happened
Roivant Sciences Ltd. filed a Current Report on Form 8-K (Item 7.01) on August 27, 2026, disclosing that the U.S. Food and Drug Administration approved the New Drug Application for LISRAYA™ (brepocitinib). The application was submitted by Roivant’s subsidiary, Priovant Therapeutics, Inc., and the company issued a press release about the approval that is attached as Exhibit 99.1 to the 8-K.

Key Details

• FDA approved the New Drug Application for LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis.
• Disclosure made via Form 8-K under Item 7.01 (Regulation FD Disclosure) and press release dated August 27, 2026 (Exhibit 99.1).
• The application was submitted by Priovant Therapeutics, Inc., a subsidiary of Roivant Sciences Ltd.

Why It Matters
An FDA approval is a material regulatory milestone for Roivant and its subsidiary Priovant: it clears the way for commercialization of LISRAYA in the approved indication in the U.S. For investors, this shifts the program from regulatory risk toward potential market launch and revenue generation, and may affect Roivant’s development and commercial plans for the drug. The 8-K furnishes the press release but does not include financial projections or commercialization details.